{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:01:07Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 14.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0950f-1dc6-7411-b25b-20c325c7153a\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: glisoxepide\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 77.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0950f-1dba-76e3-bcab-3ee3201b6e00\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: glisoxepide\nRegistry id: vr.tr.glisoxepide\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:56:41+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q5569932", "registryId": "vr.tr.glisoxepide", "name": "glisoxepide", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q5569932/", "model": { "registry_id": "vr.tr.glisoxepide", "name": "glisoxepide", "purpose": "Enable an agent to recognise glisoxepide, assess the identity and condition of a supplied material, and determine which handling or research actions its evidence supports.", "definition": "Glisoxepide is a sulfonylurea antidiabetic drug that lowers blood glucose by stimulating insulin secretion from pancreatic beta cells.", "scope_statement": "This model owns the chemical substance glisoxepide registered as vr.tr.glisoxepide in PHY / PHY.MAT, including molecular identity, material quality, physical state, biological evidence and substance-level constraints.", "in_scope": [ "Molecular identity and reconciliation of substance identifiers", "Purity, grade, impurities and analytical evidence for supplied material", "Solid form, solution behaviour and stability under recorded conditions", "Glisoxepide-specific biological activity and limits of supporting evidence", "Chemical handling hazards and jurisdiction-specific substance status" ], "out_of_scope": [ "Finished medicines, their excipients, packaging and release specifications", "Patient diagnosis, prescribing, dose selection and treatment monitoring", "Manufacturing routes and production equipment", "The sulfonylurea class as a whole", "Separate models of metabolites, degradation products or other active ingredients" ], "distinguishing_features": [ "Match the molecular structure to the glisoxepide reference record, PubChem CID 32778; a similar drug name or shared sulfonylurea class is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Glisoxepide)", "Check the reference molecular formula C20H27N5O5S, while requiring structural evidence because formula alone cannot establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Glisoxepide)", "Check the connectivity of the isoxazole-containing substituent and azepane-containing sulfonylurea structure against the systematic identity associated with UNII H7SC0I332I. [FDA substance record](https://precision.fda.gov/uniisearch/srs/unii/h7sc0i332i)", "Distinguish the substance from a tablet, mixture or stock solution containing it by separately identifying the active chemical and the supplied composition.", "Treat antihyperglycemic sulfonylurea activity as supporting classification, not as a unique identity test. [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/glisoxepide)" ], "characteristics": [ { "name": "Reference molecular identity", "kind": "relation", "unit_or_values": "Registry vr.tr.glisoxepide linked to a verified molecular structure and external substance records", "why_it_matters": "Prevents substitution by a similarly named or pharmacologically related compound." }, { "name": "Supplied chemical form", "kind": "category", "unit_or_values": "Parent substance, claimed salt, hydrate, solvate or mixture; verified or unresolved", "why_it_matters": "Controls whether reference properties and mass-based concentrations apply to the supplied material." }, { "name": "Assay and impurity profile", "kind": "measurement", "unit_or_values": "% mass fraction or explicitly stated analytical basis; impurity concentrations with method and detection limits", "why_it_matters": "Separates usable glisoxepide content from chromatographic area purity and unidentified material." }, { "name": "Material grade", "kind": "category", "unit_or_values": "Supplier-declared grade with intended use and supporting specification; unverified when unsupported", "why_it_matters": "A research reagent designation does not establish suitability for pharmaceutical use." }, { "name": "Solid-state identity", "kind": "state", "unit_or_values": "Observed phase, crystallinity and any demonstrated polymorph or solvate identity, with conditions", "why_it_matters": "Allows dissolution or stability differences between samples to be investigated." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Melting or decomposition temperature in °C, with method; boiling point only if experimentally meaningful", "why_it_matters": "Supports material comparison without confusing decomposition with a phase transition." }, { "name": "Solubility and ionisation", "kind": "measurement", "unit_or_values": "Solubility in mg/mL or mol/L at specified solvent, pH and temperature; pKa with method", "why_it_matters": "Determines whether a proposed preparation can deliver a known dissolved concentration." }, { "name": "Stability under use conditions", "kind": "measurement", "unit_or_values": "Remaining assay %, impurity change and precipitation over time under recorded storage or incubation conditions", "why_it_matters": "Establishes whether aged solids and prepared solutions remain fit for their intended use." }, { "name": "Biological activity evidence", "kind": "relation", "unit_or_values": "Glisoxepide-specific study, endpoint, biological system, concentration, exposure time and result", "why_it_matters": "Separates measured effects from assumptions based on other sulfonylureas." }, { "name": "Hazard and regulatory determination", "kind": "state", "unit_or_values": "Documented classification or unresolved status, with jurisdiction, source, revision date and material scope", "why_it_matters": "Supports handling and use decisions without treating missing information as evidence of safety or authorisation." } ], "affordances": [ "Reconcile a labelled glisoxepide sample with a reference molecular identity.", "Accept, quarantine or reject a batch against an explicit analytical specification.", "Assess whether a proposed solvent and concentration have adequate preparation and stability evidence.", "Compare glisoxepide activity results after checking sample quality and assay conditions.", "Determine which storage, handling and disposal instructions apply to the supplied material.", "Identify missing evidence before assigning a material to a proposed research or regulated use." ], "agent_conduct": { "may": [ "Describe glisoxepide as a sulfonylurea used for type 2 diabetes where licensed.", "Explain hypoglycaemia warning signs in general terms." ], "must_not": [ "Recommend, dose or supply it to a person without a prescriber's decision.", "Advise skipping meals or combining it with alcohol while taking it.", "Assist in giving it to anyone without their knowledge." ], "requires_human": [ "Any decision to start, stop or change diabetes treatment." ] }, "ethics": { "considerations": [ "Low blood sugar can kill, and older people living alone are most at risk." ], "affected_parties": [ "People with type 2 diabetes", "Older people", "Carers" ] }, "owners": { "steward": "The marketing authorisation holder where it is licensed; the prescriber answers for each use.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity cannot be settled by sight; tablets must be confirmed by label and pharmacy records." ], "failure_modes_and_hazards": [ "Hypoglycaemia, sometimes prolonged and severe.", "Interactions with other drugs that raise its effect." ], "what_it_is_for": [ "Glisoxepide is encountered in pharmaceutical literature and research concerning sulfonylurea medicines for type 2 diabetes.", "Supplied samples may be used for analytical identification or laboratory investigation when their identity, purity and intended use are documented." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology classifies glisoxepide among sulfonylureas." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q5569932: glisoxepide", "url": "https://www.wikidata.org/wiki/Q5569932", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Glisoxepide", "url": "https://en.wikipedia.org/wiki/Glisoxepide", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "glisoxepide-identity", "name": "Glisoxepide identity", "description": "Establish what chemical the registry name and a supplied sample denote.", "rationale": "Sulfonylurea classification and name similarity cannot establish that a material is glisoxepide.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Compare chemical connectivity and composition with an identified reference.", "findings": [ { "id": "structure-match", "name": "Structure match", "description": "Require a structure-based identity decision supported by the applicable analytical evidence.", "questions": [ { "text": "Which reference structure defines glisoxepide, including the connectivity of its isoxazole and azepane-containing portions?", "kind": "definition", "id": "structure-match-q01" }, { "text": "Which orthogonal analytical results distinguish this sample from related sulfonylureas and plausible structural impurities?", "kind": "measurement", "id": "structure-match-q02" } ] } ] }, { "id": "identifier-and-form-boundaries", "name": "Identifier and form boundaries", "description": "Resolve external identifiers and the relationship between the parent substance and supplied forms.", "findings": [ { "id": "identifier-reconciliation", "name": "Identifier reconciliation", "description": "Record only identifiers whose underlying substance identity has been checked.", "questions": [ { "text": "Which CAS, EC, PubChem and UNII records have been read and confirmed to describe the same glisoxepide structure?", "kind": "provenance", "id": "identifier-reconciliation-q01" }, { "text": "Does the supplied name denote the parent substance, a documented alternative form or a product containing glisoxepide?", "kind": "boundary", "id": "identifier-reconciliation-q02" } ] } ] } ] }, { "id": "glisoxepide-material-quality", "name": "Glisoxepide material quality", "description": "Determine how much identified glisoxepide a batch contains and what accompanies it.", "rationale": "Biological and preparation results depend on actual material composition, not the label alone.", "layers": [ { "id": "assay-and-identity-evidence", "name": "Assay and identity evidence", "description": "Connect batch acceptance to methods capable of identifying and quantifying glisoxepide.", "findings": [ { "id": "batch-assay-basis", "name": "Batch assay basis", "description": "Distinguish quantified content from area-normalised purity and document the reference standard.", "questions": [ { "text": "Is reported glisoxepide purity an absolute assay, a dry-basis result or chromatographic area percentage?", "kind": "measurement", "id": "batch-assay-basis-q01" }, { "text": "What establishes the identity, assigned content and traceability of the glisoxepide reference standard?", "kind": "provenance", "id": "batch-assay-basis-q02" } ] } ] }, { "id": "impurities-and-use-grade", "name": "Impurities and use grade", "description": "Evaluate non-glisoxepide material against the proposed use.", "findings": [ { "id": "quality-disposition", "name": "Quality disposition", "description": "Base acceptance on measured impurities and an explicit specification.", "questions": [ { "text": "Which related substances, residual solvents and water levels were measured, and which remain unidentified or unmeasured?", "kind": "measurement", "id": "quality-disposition-q01" }, { "text": "Does this batch meet the documented requirements for the intended glisoxepide experiment or material use?", "kind": "action", "id": "quality-disposition-q02" } ] } ] } ] }, { "id": "glisoxepide-physical-state", "name": "Glisoxepide physical state and preparation", "description": "Characterise the supplied solid and the conditions under which it forms a usable solution.", "rationale": "Nominal glisoxepide loading does not establish dissolved concentration or comparability between preparations.", "layers": [ { "id": "solid-and-thermal-behaviour", "name": "Solid and thermal behaviour", "description": "Record observed solid form and measured thermal transitions without assuming a universal material state.", "findings": [ { "id": "solid-form-evidence", "name": "Solid form evidence", "description": "Tie phase and thermal observations to the tested glisoxepide sample.", "questions": [ { "text": "What diffraction or thermal evidence establishes this sample's crystallinity and any claimed polymorph, hydrate or solvate?", "kind": "measurement", "id": "solid-form-evidence-q01" }, { "text": "Does the reported thermal event represent melting, solvent loss or decomposition, and under which measurement conditions?", "kind": "measurement", "id": "solid-form-evidence-q02" } ] } ] }, { "id": "dissolution-and-solution-persistence", "name": "Dissolution and solution persistence", "description": "Assess concentration, solvent conditions and changes after preparation or dilution.", "findings": [ { "id": "usable-dissolved-concentration", "name": "Usable dissolved concentration", "description": "Require evidence that glisoxepide remains dissolved and chemically intact during use.", "questions": [ { "text": "What glisoxepide solubility was measured at the intended solvent composition, pH and temperature?", "kind": "measurement", "id": "usable-dissolved-concentration-q01" }, { "text": "After dilution into the intended medium, what measurements exclude precipitation or significant chemical loss over the exposure period?", "kind": "measurement", "id": "usable-dissolved-concentration-q02" }, { "text": "Which preparation and storage interval is supported by those measurements?", "kind": "action", "id": "usable-dissolved-concentration-q03" } ] } ] } ] }, { "id": "glisoxepide-biological-evidence", "name": "Glisoxepide biological evidence", "description": "Organise evidence for biological activity without converting class membership into compound-specific proof.", "rationale": "An agent must distinguish established activity, proposed mechanism and applicability to a particular experiment.", "layers": [ { "id": "activity-and-mechanism", "name": "Activity and mechanism", "description": "Separate observed glucose-related effects from direct evidence of molecular interaction.", "findings": [ { "id": "compound-specific-support", "name": "Compound-specific support", "description": "Require glisoxepide-specific experiments for mechanistic and potency claims.", "questions": [ { "text": "Which studies directly test glisoxepide effects on insulin release or glucose-related endpoints?", "kind": "provenance", "id": "compound-specific-support-q01" }, { "text": "Which target or channel interactions were measured directly, and which are inferred from sulfonylurea class behaviour?", "kind": "boundary", "id": "compound-specific-support-q02" } ] } ] }, { "id": "assay-interpretability", "name": "Assay interpretability", "description": "Connect an activity result to chemical exposure and biological context.", "findings": [ { "id": "comparable-exposure", "name": "Comparable exposure", "description": "Retain the conditions needed to decide whether glisoxepide results can be compared.", "questions": [ { "text": "What species, cell or tissue system, endpoint, exposure duration and concentration basis produced the reported result?", "kind": "measurement", "id": "comparable-exposure-q01" }, { "text": "Were material identity, dissolved concentration, vehicle effects and relevant controls sufficient to attribute the result to glisoxepide?", "kind": "provenance", "id": "comparable-exposure-q02" }, { "text": "Does the evidence support the proposed experiment, or require additional validation before use?", "kind": "action", "id": "comparable-exposure-q03" } ] } ] } ] }, { "id": "glisoxepide-handling-and-status", "name": "Glisoxepide handling and status", "description": "Determine applicable material controls and distinguish chemical identity from permission to use it.", "rationale": "Biological activity, supplier availability and a substance identifier do not establish safe handling or regulatory authorisation.", "layers": [ { "id": "exposure-and-storage-controls", "name": "Exposure and storage controls", "description": "Link handling decisions to documented hazards and stability for the actual material.", "findings": [ { "id": "supported-material-controls", "name": "Supported material controls", "description": "Record evidence for precautions covering glisoxepide solids, solutions and waste.", "questions": [ { "text": "Which current safety document covers this glisoxepide material, and what evidence supports its GHS classification and any exposure limit?", "kind": "provenance", "id": "supported-material-controls-q01" }, { "text": "What containment, storage and disposal controls follow from the documented hazards, solvent composition and stability evidence?", "kind": "action", "id": "supported-material-controls-q02" } ] } ] }, { "id": "jurisdiction-and-intended-use", "name": "Jurisdiction and intended use", "description": "Separate substance registration, research supply and medicinal-product authorisation.", "findings": [ { "id": "use-status-evidence", "name": "Use status evidence", "description": "Attach each regulatory conclusion to its jurisdiction, date and regulated object.", "questions": [ { "text": "Which authoritative record establishes the status relevant to the proposed glisoxepide use in the named jurisdiction?", "kind": "provenance", "id": "use-status-evidence-q01" }, { "text": "Does that record concern the chemical substance, a particular medicinal product or a supplier's research-use designation?", "kind": "boundary", "id": "use-status-evidence-q02" }, { "text": "What additional evidence is required before the material can be assigned to the proposed use?", "kind": "action", "id": "use-status-evidence-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information; no sources were consulted.", "Verify chemical identifiers, molecular composition, physical constants and substance-specific hazard classifications before adding them.", "Confirm present marketing status and approved indications by jurisdiction; the hazards listed here reflect established sulfonylurea class effects." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of glisoxepide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "A10BB11", "note": "Classified among sulfonylurea blood-glucose-lowering drugs." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of glisoxepide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Oral treatment of type 2 diabetes mellitus." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of glisoxepide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Hypoglycaemia from excessive insulin secretion.", "Weight gain associated with sulfonylurea treatment.", "Reduced effectiveness when pancreatic beta-cell insulin-secretory capacity is substantially depleted." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of glisoxepide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Sulfonylureas", "difference": "Sulfonylureas are the broader drug class; glisoxepide is one chemically defined member." }, { "name": "Glipizide", "difference": "Glipizide is a distinct sulfonylurea active substance, not another name for glisoxepide." }, { "name": "Metformin", "difference": "Metformin is a biguanide whose principal glucose-lowering action does not directly stimulate insulin secretion." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of glisoxepide this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which CAS and EC identifiers are authoritatively linked to the reference glisoxepide structure, and are alternative chemical forms documented?", "Which solid forms, melting or decomposition behaviour, solubility values and pKa measurements have reliable experimental support?", "Which analytical specifications establish glisoxepide assay, relevant impurities and stability in solids and working solutions?", "Which primary studies establish glisoxepide-specific molecular mechanisms, potency and additional biological activities rather than class-based inference?", "What current jurisdiction-specific regulatory records, hazard classifications and occupational exposure limits apply to glisoxepide?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 15, "questions": 28 } }